Risks of chronic hypnotic use

Sleep and Sleep Disorders: A Neuropsychopharmacological Approach

Volumn , Issue , 2006, Pages 141-145

  Kripke, Daniel F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52649170479     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-27682-3_15     Document Type: Chapter

References (57)

1. Kripke DF. Chronic hypnotic use: He neglected problem. In: Koella WP, Ruther E, Schulz H, eds. Sleep '84. Stuttgart: Gustav Fischer Verlag, 1985:338-340.
2. Kripke DF, Klauber MR, Wingard DL et al. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998; 43:687-693.
3. Ohayon MM, Caulet M. Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychiatry 1996; 41:457-464.
4. Balestrieri M, Bortolomasi M, Galletta M et al. Patterns of hypnotic drug prescription in Italy Brit J Psychiat 1997; 170:176-180.
5. Rayon P, Castro-Serrano M, del Barrio H et al. Hypnotic drug use in Spain: A cross-sectional study based on a network of community pharmacies. Pharmacoepidemiology 1996; 30:1092-1100.
6. Kripke DF, Simons RN, Garfmkel L et al. Short and long sleep and sleeping pills: Is increased mortality associated? Arch Gen Psychiatry 1979; 36:103-116.
7. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002; 59:131-136.
8. Kripke DF, Marler MR. Specific causes of mortality associated with prescription sleeping pill usage [abstraa]. Sleep Research Online 1999; 2:144.
9. Allgulander C, Nowak J, Rice JP. Psychopathology and treatment of 30, 344 twins in Sweden. I. The appropriateness of psychoaaive drug treatment. Aaa Psychiatrica Scandinavica 1990; 82:420-426.
10. Allgulander C, Ljungberg L, Fisher LD. Long-term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model. Aaa Psychiatrica Scandinavica 1987; 75:521-531.
11. Thorogood M, Cowen P, Mann J et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992; 340:1067-1068.
12. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc 1992; 40:787-791.
13. Brabbins CJ, Dewey ME, Copeland RM et al. Insomnia in the elderly: Prevalence, gender differences and relationships with morbidity and mortality. Int J Ger Psych 1993; 8:473-480.
14. Sundquist J, Ekedahl A, Johansson S-E. Sales of tranquillizers, hypnotics/sedatives and antidepressants and their relationship with underprivileged area score and mortality and suicide rates. Eur J Clin Pharmacol 1996; 51:105-109.
15. Merlo J, Hedblad B, Ogren M et al. Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics. Eur J Clin Pharmacol 1996; 49:261-265.
16. Hays JC, Blazer DG, Foley DJ. Risk of napping: Excessive daytime sleepiness and mortality in an older community population. J Am Geriatr Soc 1996; 44:693-698.
17. Kojima M, Wakai K, Kawamura T et al. Sleep patterns and total mortality: A 12-year follow-up study in Japan. J Epidemiol 2000; 10:87-93.
18. Mallon L, Broman J-E, Hetta J. Sleep complaints predict coronary artery disease mortality in males: A 12-year follow-up study of a middle-aged Swedish popularion. J Int Med 2002; 251:207-216.
19. Lapane KL, Zierler S, Lasater TM et al. Is the use of psychotropic drugs associated with increased risk of ischemic heart disease? Epidemiology 1995; 6:376-381.
20. Pratt LA, Ford DE, Crum RM et al. Depression, psychotropic medication, and risk of myocardial infaraion. Prospeaive data from the Baltimore EGA follow-up. Circulation 1996; 94:3123-3129.
21. Ohayon MM, Caulet M, Arbus L et al. Are prescribed medications effective in the treatment of insomnia complaints? J Psychosom Res 1999; 47:359-368.
22. Leger D, Janus C, Pellois A et al. Sleep, morning alertness and quality of life in subjects treated with zopiclone and in good sleepers. Study comparing 167 patients and 381 good sleepers. Eur Psychiatry 1995; 10:99s-102s.
23. Ohayon M, Caulet M, Lemoine P. Sujets agés, habitudes de sommeil et consommation de psychotropes dan la population française. L'Encephale 1996; 22:337-350.
24. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002; 63:817-825.
25. Morin CM, Bastien CH, RadoucoThomas M. Late-life insomnia and chronic use of benzodiazepines: Medication tapering with and without behavioral intervention [abstract]. Sleep 1998; 21S:99.
26. Parrino L, Smerieri A, Boselli M et al. Discontinuation of elevated doses of benzodiazepines used as hypnotics: Polysomnographic assessment of sleep parameters [abstract]. Sleep 1998; 21S: 101.
27. Kales A, Soldatos CR, Bixler EO et al. Early morning insomnia with rapidly eliminated benzodiazepines. Science 1983; 220:95-7.
28. Kales A, Soldatos CR, Bixler EO et al. Rebound insomnia and rebound anxiety: A review. Pharmacology 1983; 26:121-37.
29. Walsh JK. Reply to Kripke. Sleep Medicine Reviews 2003; 7:195-196.
30. Elan Pharmaceuticals: Sonata (zaleplon) Capsules. 11/26/2001 [prescribing information]. Philadelphia, PA: Wyeth Laboratories, 2002.
31. George CFP. Pyrazolopyrimidines. Lancet 2001; 357:1623-1626.
32. Mider MM, Seidel WF, van den Hoed J et al. Comparative hypnotic effects of flurazepam, triazolam, and placebo: A long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol 1984; 4:2-15.
33. Kripke DF, Hauri P, Ancoli-Israel S et al. Sleep evaluation in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990; 10(Supplement 4):32S-43S.
34. Scharf MB, Roth T, Vogel GW et al. A multicenter, placebo-controlled study evaluating Zolpidem in the treatment of chronic insomnia. J CUn Psychiatry 1994; 55:192-199.
35. Oswald I, French C, Adam K et al. Benzodiazepine hypnotics remain effeaive for 24 weeks. Bristish Medical Journal 1982; 284:860-863.
36. Judd LL, Ellinwood E, McAdams LA. Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990; 10:56S-67S.
37. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology (Berlin) 1982; 76:101-113.
38. Walsh JK, Roth T, Randazzo A et al. Eight weeks of nonnightly use of Zolpidem for primary insomnia. Sleep 2000; 23:1087-1096.
39. Barbone F, McMahon AD, Davey PC et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352:1331-1336.
40. Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: A report from the Boston collaborative drug surveillance program. Br J Clin Pharmacol 1978; 5:407-13.
41. Hemmelgarn B, Suissa S, Huang A et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly JAMA 1997; 278:27-31.
42. Oster G, Huse DM, Russell MW et al. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 1990; 80:1467-1470.
43. Ray WA, Griffin MR, Schaffiier W et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316:363-9.
44. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319(26):1701-1707.
45. Ray WA, Griffin MR, Downey W Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23):3303-3307.
46. Greenblatt DJ, Harmatz JS, Engelhardt N et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: Flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 1989; 46:326-332.
47. Allgulander C, Nasman B. Regular hypnotic drug treatment in a sample of 32, 679 Swedes: Associations with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record-linkage. Psychosom Med 1991; 53(1): 101-108.
48. Quera-Salva MA, Orluc A, Goldenberg F et al. Insomnia and use of hypnotics: Study of a French population. Sleep 1991; 14(5):386-391.
49. Roehrs T, HoUebeek E, Drake C et al. Substance use for insomnia in Metropohtan Detroit. J Psychosom Res 2002; 53:571-576.
50. Byles JE, Mishra CD, Harris MA et al. The problems of sleep for older women: Changes in health outcomes. Age Ageing 2003; 32:154-163.
51. Morin CM, Colecchi C, Stone J et al. Behavioral and pharmacological therapies for late-life insomnia. A randomized controlled trial. JAMA 1999; 281:991-999.
52. Kripke DF. Chronic hypnotic use: Deadly risks, doubtful benefit. Sleep Medicine Reviews 2000; 4:5-20.
53. Kripke DF http://www.DarkSideOfSleepingPills.com 2002.
54. NIOM: Sleeping Pills, Insomnia, and Medical Practice. Washington DC: National Academy of Sciences, 1979:1-198.
55. Consensus Conference: Drugs and insomnia. The use of medications to promote sleep. JAMA 1984; 251(18):2410-2414.
56. National Institutes of Health: Consensus development conference statement: The treatment of sleep disorders of older people. Sleep 1991; 14(2):169-177.
57. Bunney Jr WE, Azarnoff DL, Brown Jr BW et al. Report of the institute of medicine committee on the efficacy and safety of Halcion. Arch Gen Psychiatry 1999; 56:349-352.